Indian Pharmaceutical Startups Leverage Artificial Intelligence to Accelerate Drug Discovery
Indian startup Peptris is utilizing artificial intelligence to advance multiple drug development programmes simultaneously, achieving late preclinical stages in roughly 18 months instead of the traditional four years. According to co-founder Venkatasubramanian Narayanan, artificial intelligence significantly reduces the required capital. Industry scientists note this technological shift could expand India's pharmaceutical sector beyond its historical strengths in generics, contract research, and manufacturing. Prime Minister Narendra Modi highlighted the nation's scale at the Bloomberg New Economy Forum, stating that India supplies one in five global generic medicines.
Originally published by CNA | By Shadma Shaikh | 16 October 2026 | Read original: https://www.channelnewsasia.com/asia/ai-lowers-capital-needed-indias-drug-discovery-push-faces-test-human-trials-6462176
More from India's Pulse